Novel infectious pathogens can pose major challenges to global health and security. Tracking the geography, demographics, and suspected mode of transmission of these pathogens by using a standardized case definition remains the foundation for infectious disease surveillance (1). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease (COVID-19), was first characterized in December 2019 (2). By January 2020, the first national case definition was developed (3) and the World Health Organization (WHO) declared a public health emergency of international concern (4). WHO’s interim guidance for global COVID-19 surveillance, released on January 31, 2020, provided a hierarchy of confirmed, probable, and suspected case definitions (5). This guidance encouraged the use of all available clinical, epidemiologic, and laboratory evidence for case classification purposes and noted that countries might need to adapt these definitions to their unique epidemiologic situations. Recommendations for testing suspected cases and widespread testing on the basis of transmission intensity, number of cases, and available resources were included.

Both WHO and national case definitions have evolved as knowledge about COVID-19 etiology and the myriad of ways the disease manifests after infection has grown (5–7). Early on, surveillance emphasized a travel history to Wuhan, China, where the initial outbreak occurred, and a narrowly defined set of symptoms. However, the virus rapidly spread to other provinces in China and then internationally, and reports of patients who experienced new symptoms or remained asymptomatic increased (8). Confirming a COVID-19 case relies on diagnostic testing; therefore, testing capacity has played a vital role in COVID-19 surveillance efforts. The types of tests available have expanded to include molecular and antigen tests to detect the presence of the SARS-CoV-2 virus and serologic tests to detect antibodies produced from previous SARS-CoV-2 infection (9,10). However, the availability of these tests and the resources needed to collect, handle, and process clinical specimens have varied widely across nations (11). Shortages of test kits and reagents and lack of laboratory capacity have forced officials in many locations to make difficult decisions about testing eligibility (12).

We compared case definitions for suspected, probable, and confirmed coronavirus disease (COVID-19), as well as diagnostic testing criteria, used in the 25 countries with the highest reported case counts as of October 1, 2020. Of the identified countries, 56% followed World Health Organization (WHO) recommendations for using a combination of clinical and epidemiologic criteria as part of the suspected case definition. A total of 75% of identified countries followed WHO recommendations on using clinical, epidemiologic, and diagnostic criteria for probable cases; 72% followed WHO recommendations to use PCR testing to confirm COVID-19. Finally, 64% of countries used testing eligibility criteria at least as permissive as WHO. We observed marked heterogeneity in testing eligibility requirements and how countries define a COVID-19 case. This heterogeneity affects the ability to compare case counts, transmission, and vaccine effectiveness, as well as estimates derived from case surveillance data across countries.

Amitabh B. Suthar,1 Sara Schubert,1 Julie Garon, Alexia Couture, Amy M. Brown, Sana Charania

1These authors contributed equally to this article.

Author affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

DOI: https://doi.org/10.3201/eid2801.211082
Differences in testing eligibility criteria and case definitions pose a challenge not only to detecting the actual number of cases within countries, but also to understanding the global burden of disease and adequately responding to pandemics. Global guidelines have been developed for testing eligibility criteria and case definitions but are usually reviewed at a national level and are subject to adaptation on the basis of laboratory and health system considerations. Earlier evaluations of global COVID-19 case definitions do not reflect the latest changes to national case definitions and testing eligibility criteria and do not target the full range of countries with the highest number of reported COVID-19 cases (13–15). We analyzed national COVID-19 case definitions from the 25 countries with the largest number of reported COVID-19 cases as of October 1, 2020 (collectively representing ≈85% of the global cases at that time), and the specific criteria used to determine eligibility for diagnostic testing. We also determined the implications of intercountry differences on ongoing efforts to understand global disease burden and control the pandemic.

Methods

Design
We identified the 25 countries with the highest number of reported COVID-19 cases from WHO COVID-19 cumulative case counts as of October 1, 2020 (16). We extracted surveillance case definitions and official testing policies from official government Web sites for the respective countries. If definitions were not available on government Web sites, we extracted definitions from personal communication with Centers for Disease Control and Prevention field staff.

To find these data, we searched government Web sites using these keywords: case definition, suspect case, confirmed case, COVID-19, case criteria, surveillance, testing criteria, guidelines, laboratory, reverse transcription PCR (RT-PCR), and asymptomatic. All surveillance definitions and testing criteria were verified current as of January 1, 2021. Several official policies were not available in English. For these documents, we used Google Translate (https://translate.google.com) to identify definitions and testing policies.

Data Management and Analysis
To compare case definitions across countries, we classified the components of each definition into 3 parts: diagnostic components including a laboratory test or radiographic imagery; clinical signs and symptoms, such as cough, fever, and severe acute respiratory infection; and epidemiologic criteria, including travel to a high-burden region or contact with a confirmed or suspected case. For each country’s testing policy, we reviewed which persons were eligible for diagnostic testing. Countries were classified as testing asymptomatic persons without any additional criteria; testing asymptomatic persons with some epidemiologic criteria, such as contact with a confirmed case; or recommending testing exclusively for symptomatic persons. These analyses were based solely on diagnostic testing eligibility criteria and did not consider exceptions, such as testing asymptomatic persons before travel, asymptomatic testing through the private sector, or local-level mass testing. Exceptions to national testing policies varied on a local level and frequently changed, which made data difficult to procure and unreliable. We compared elements of national case definitions and testing criteria against global norms from WHO.

Source Assessment
To assess sources, we extracted information on their origin (government source or personal communication) and timeliness (date of publication). We compiled the date of publication and presumed implementation of each country’s most recent case definition as verified on January 1, 2021 (Appendix Table 1, https://wwwnc.cdc.gov/EID/article/28/1/21-1082-App1.pdf). Publication dates range from March 27, 2020, to December 18, 2020, for case definitions and July 6, 2020, to January 1, 2021, for testing policies.

Results

Suspected Case Definitions
We identified suspected case definitions in 24 (96%) of 25 countries (Table 1; Appendix Tables 2,3). Although Israel does not have an official suspected case definition, persons are considered suspected on the basis of contact with confirmed cases, which is determined by digital surveillance of cellphones. We interpreted Israel’s suspected contact determined by cellphones to be an epidemiologic criterion. The 3 most common criteria in suspected case definitions were fever (reported in 92% of countries), cough (reported in 84% of countries), and labored breathing (reported in 84% of countries). In 7 countries (28%), other criteria were used in addition to common criteria (Table 1). The WHO suspected case definition relies on clinical symptoms, including the 3 most common, and epidemiologic criteria. A total of 14 (56%) countries followed this guidance broadly by using clinical and
probable case definitions in 16 (64%) of 25 countries (Table 2; Appendix Tables 4,5). The remaining 9 (36%) countries chose not to use a probable case definition and instead use only suspected and confirmed case definitions. The WHO probable case definition includes criteria from all 3 categories: diagnostic testing (chest imaging), clinical symptoms, and epidemiologic criteria. Of the 16 countries, 12 (75%) were consistent with WHO and included criteria from all 3 categories. The number of required criteria across countries was heterogeneous. The 3 most common criteria in probable case definitions were fever (reported in 94% of 16 countries), labored breathing (reported in 88% of 16 countries), and confirmed contact with a probable or confirmed case (reported in 81% of 16 countries). Fourteen (88%) countries included diagnostic testing for the probable case definition, 15 (94%) included clinical symptoms in their definitions, and 14 (88%) included epidemiologic criteria.

Probable Case Definitions
We identified probable case definitions in 16 (64%) of 25 countries (Table 2; Appendix Tables 4,5). The remaining 9 (36%) countries chose not to use a probable case definition and instead use only suspected and confirmed case definitions. The WHO probable case definition includes criteria from all 3 categories: diagnostic testing (chest imaging), clinical symptoms, and epidemiologic criteria. Of the 16 countries, 12 (75%) were consistent with WHO and included criteria from all 3 categories. The number of required criteria across countries was heterogeneous. The 3 most common criteria in probable case definitions were fever (reported in 94% of 16 countries), labored breathing (reported in 88% of 16 countries), and confirmed contact with a probable or confirmed case (reported in 81% of 16 countries). Fourteen (88%) countries included diagnostic testing for the probable case definition, 15 (94%) included clinical symptoms in their definitions, and 14 (88%) included epidemiologic criteria.
COVID-19 Definitions, Testing, and Surveillance

Confirmed Case Definitions
We identified confirmed case definitions in all 25 countries (100%) (Table 3; Appendix Tables 6, 7). All confirmed case definitions required diagnostic testing. A total of 18 (72%) countries were consistent with WHO’s recommendations and specified RT-PCR tests in their case definition. Of these countries, 10 (40%) also included antigen or antibody tests in their definition. In 7 (28%) countries, the type of diagnostic test was not specified. Reference to the suspected case definition within the confirmed case definition was included in 7 (28%) of countries. Of these, Mexico, Saudi Arabia, and Turkey required that a person meet the suspected case definition in addition to diagnostic testing criteria. In addition to confirming cases on the basis of diagnostic testing, 6 (24%) countries confirmed cases exclusively on the basis of loss of taste or smell (anosmia or ageusia). Overall, 8 countries (32%) included clinical symptoms as part of their confirmed case definition.

Testing Eligibility Criteria
We identified testing criteria in all 25 countries (100%) (Appendix Table 8). Of those, 8 (32%) countries had no symptom requirements for testing, 8 (32%) had no symptom requirements for testing but required epidemiologic criteria (i.e., exposure to a confirmed or probable case), and 9 (36%) countries required symptoms. Of the 8 countries requiring epidemiologic criteria, 5 (63%) also allowed testing for asymptomatic healthcare workers (Appendix Table 8). Policies from Saudi Arabia and the United Kingdom specified not to test asymptomatic persons but included an exception for healthcare workers (Appendix Table 8). WHO recommends testing asymptomatic persons who have had contact with a confirmed case; 64% of countries used eligibility criteria at least as permissive as WHO.

Source Assessment
We found 92% of case definitions on government Web sites, and 72% were published or included in

Table 2. Selected probable case definition criteria across 25 countries with the highest COVID-19 case counts, current as of January 1, 2021*

| Country           | Diagnostic testing | Clinical symptoms |  | Epidemiologic criteria |
|-------------------|--------------------|-------------------|---|------------------------|
|                   | Inconcl. test      | Antigen test      | Radiograph imaging | Cough | Fever | SARI | Labored breathing | Loss of taste or smell | Travel history | Hosp. | Confirmed contact |
| WHO definition    | X                  |                    |                    | X     | X     | X    | X                | X                   | X               | X     | X               |
| reference         |                    |                    |                    |       |       |      |                  |                     |                 |       |                 |
| Argentina         |                    |                    |                    |       |       |      |                  |                     |                 |       |                 |
| Bangladesh†       |                    |                    |                    |       |       |      |                  |                     |                 |       |                 |
| Brazil            |                    |                    |                    |       |       |      |                  |                     |                 |       |                 |
| Chile             | X                   | X                  | X                  | X     | X     | X    | X                | X                   | X               | X     |                 |
| Colombia          | X                   |                    |                    | X     | X     | X    | X                | X                   | X               | X     |                 |
| France‡           | X                   |                    |                    | X     |       | X    | X                | X                   | X               | X     |                 |
| Germany‡          |                    | X                  | X                  | X     |       | X    | X                | X                   | X               | X     |                 |
| India§            |                    | X                  |                    |       |       | X    | X                |                     | X               | X     |                 |
| Indonesia         |                    |                    |                    |       |       | X    |                  |                     |                 |       |                 |
| Iran              | X                   |                    |                    |       |       |      |                  |                     |     X            | X     |                 |
| Iraq†             | X                   |                    |                    |       |       |      |                  |                     |                 |       |                 |
| Israel            |                    |                    |                    |       |       |      |                  |                     |                 |       |                 |
| Italy‡            |                    |                    |                    |       |       |      |                  |                     |                 |       |                 |
| Mexico            | X                   |                    |                    |       |       |      |                  |                     |                 |       |                 |
| Pakistan§         | X                   |                    |                    |       |       |      |                  |                     |                 |       |                 |
| Peru              |                    |                    |                    |       |       |      |                  |                     |                 |       |                 |
| Philippines†      |                    | X                  |                    |       |       |      |                  |                     |                 |       |                 |
| Russia            | X                   |                    |                    |       |       |      |                  |                     |                 |       |                 |
| Saudi Arabia      |                    |                    |                    |       |       |      |                  |                     |                 |       |                 |
| South Africa      |                    |                    |                    |       |       |      |                  |                     |                 |       |                 |
| Spain             | X                   |                    |                    |       |       |      |                  |                     |                 |       |                 |
| Turkey            |                    |                    |                    |       |       |      |                  |                     |                 |       |                 |
| Ukraine           |                    |                    |                    |       |       |      |                  |                     |                 |       |                 |
| United Kingdom    |                    |                    |                    |       |       |      |                  |                     |                 |       |                 |
| United States     |                    |                    |                    |       |       |      |                  |                     |                 |       |                 |
| No. (%) countries | 6 (38)             | 2 (13)            | 10 (63)            | 13 (81)| 15 (94)| 11 (69)| 14 (88)          | 12 (75)             | 8 (50)         | 6 (38)| 13 (81)         |

*Complete data are available in Appendix Table 5 (https://wwwnc.cdc.gov/EID/article/28/1/21-1082-App1.pdf); full probable case definitions are shown in Appendix Table 4. X indicates the criterion was sufficient for, or a potential component of, the probable case definition requirement(s). COVID-19, coronavirus disease; hosp., hospitalized; inconcl., inconclusive; SARI, severe acute respiratory infection; WHO, World Health Organization.
†World Health Organization definition (updated August 2020).
‡European Centre for Disease Prevention and Control definition.
§World Health Organization definition (updated March 2020).
¶Denominator is 16 countries with probable case definition.
documents published after the most recent WHO definition was published (August 7, 2020) (Appendix Table 1). India and Pakistan used the previous WHO definition (dated March 2020); we could not confirm that these countries updated their definition on the basis of the newest WHO definitions. We could not locate definitions on government Web sites for Israel, Iraq, and Iran; for these countries, we obtained definitions from personnel involved in the country’s COVID-19 response. Of 25 countries, 23 (92%) had an official government source for diagnostic testing criteria. In total, 88% of testing criteria were published after September 1, 2020. The policies for Philippines, Brazil, and Pakistan were updated in July and August 2020.

Discussion

All iterations of WHO’s global COVID-19 surveillance guidance state that countries might need to adapt case definitions to their specific circumstances (5–7,19). Beginning with the March 20, 2020, version, WHO also encouraged countries to publish their adapted versions online and in periodic situation reports (6,7). Nearly all countries (92%) in this analysis chose to deviate from WHO case definitions; 92% of countries posted their case definition on a government Web site. Suspected and confirmed case classifications were found for nearly all countries, but 36% excluded the probable case classification. In addition, we observed substantial variation among testing criteria used in national case definitions. Although WHO reserved the use of laboratory testing for confirmed cases only, 2 (8%) countries included laboratory evidence for suspected cases and 14 (88%) for probable cases; 32% included nonlaboratory criteria for confirmed cases. Laboratory evidence in some countries was not restricted to RT-PCR and included increasingly available antigen and antibody tests. Testing eligibility criteria also differed widely; many countries either excluded asymptomatic persons from routine testing (36%) or only included them under certain conditions (32%).

Table 3. Selected confirmed case definition criteria across 25 countries with the highest COVID-19 case counts, current as of January 1, 2021*  

| Country         | Diagnostic testing | Clinical symptoms | Epidemiologic criteria |
|-----------------|--------------------|-------------------|------------------------|
|                 | PCR test | Antigen test | Ab test | Positive test (NS) | Radiograph imaging | Meet suspected case definition | Loss of taste or smell | Travel history | Hosp. | Confirmed contact |
| WHO definition  | X        | X          | X | X | X | X | X | X | X | X | X |
| (reference)     |          |            |          |          |          |          |            |            |      |      |      |
| Argentina       | X        | X          | X | X | X | X | X | X | X | X | X |
| Bangladesh†     | X        |            | X | X | X | X | X | X | X | X | X |
| Brazil          | X        | X          | X | X | X | X | X | X | X | X | X |
| Chile           | X        | X          | X | X | X | X | X | X | X | X | X |
| Colombia        | X        | X          | X | X | X | X | X | X | X | X | X |
| France‡         | X        | X          | X | X | X | X | X | X | X | X | X |
| Germany‡        | X        | X          | X | X | X | X | X | X | X | X | X |
| India†          | X        | X          | X | X | X | X | X | X | X | X | X |
| Indonesia       | X        | X          | X | X | X | X | X | X | X | X | X |
| Iran            | X        | X          | X | X | X | X | X | X | X | X | X |
| Iraq†           | X        | X          | X | X | X | X | X | X | X | X | X |
| Israel          | X        | X          | X | X | X | X | X | X | X | X | X |
| Italy‡          | X        | X          | X | X | X | X | X | X | X | X | X |
| Mexico          | X        | X          | X | X | X | X | X | X | X | X | X |
| Pakistan†       | X        | X          | X | X | X | X | X | X | X | X | X |
| Peru            | X        | X          | X | X | X | X | X | X | X | X | X |
| Philippines†    | X        | X          | X | X | X | X | X | X | X | X | X |
| Russia          | X        | X          | X | X | X | X | X | X | X | X | X |
| Saudi Arabia    | X        | X          | X | X | X | X | X | X | X | X | X |
| South Africa    | X        | X          | X | X | X | X | X | X | X | X | X |
| Spain           | X        | X          | X | X | X | X | X | X | X | X | X |
| Turkey          | X        | X          | X | X | X | X | X | X | X | X | X |
| Ukraine         | X        | X          | X | X | X | X | X | X | X | X | X |
| United Kingdom  | X        | X          | X | X | X | X | X | X | X | X | X |
| United States   | X        | X          | X | X | X | X | X | X | X | X | X |
| No. (% countries§ | 18 (72) | 10 (40)  | 2 (8) | 7 (28) | 1 (4) | 7 (28) | 6 (24) | 3 (12) | 4 (16) | 6 (24) |

*Complete data are available in Appendix Table 7 (https://wwwnc.cdc.gov/EID/article/28/1/21-1082-App1.pdf); X indicates the criterion was sufficient for, or a potential component of, the confirmed case definition requirement(s). Full confirmed case definitions can be found in Appendix Table 6. Ab, antibody; hosp., hospitalized; NS, not specified; WHO, World Health Organization.
†World Health Organization definition (confirmed case definition did not change between March 2020 and August 2020 update).
‡European Centre for Disease Prevention and Control definition.
§Denominator is 25 countries with confirmed case definitions.
Differences in case definitions and testing eligibility can affect efforts to monitor disease trends and determine the impact and effectiveness of vaccines across countries and over different periods. As knowledge of a novel disease increases, the sensitivity and specificity of the case definition changes over time, ultimately affecting the number of cases identified (20). For example, during the 2002–2003 severe acute respiratory syndrome outbreak, several iterations of case definitions in the Netherlands diverged from the more sensitive and less specific WHO case definition. When all cases were reevaluated, 21 cases were classified as suspected and 2 as probable according to the latest WHO case definition, as opposed to 9 suspected and zero probable cases according to the Netherlands case definitions (21). As the COVID-19 pandemic emerged in China, a February 12, 2020, change to the case definition to include clinically diagnosed mild cases resulted in identification of >15,000 cases (22). A study of successive case definitions in China, each with gradually increasing sensitivity, also yielded higher detection of cases (15). During January 15–March 3, 2020, the National Health Commission of China used 7 versions of the case definition for COVID-19; the study estimates that the proportion of cases detected increased by 7 times after the first change, 3 times from change 2 to 4, and 4 times after change 5. The authors estimated that if the fifth version of the case definition had been applied throughout the outbreak, 4.2 times more confirmed cases would have been identified in China by February 20, 2020 (232,000 vs. 55,508). A more recent study benefitting from the availability of the complete genome sequence for SARS-CoV-2 and access to respiratory specimens collected early for retrospective analysis perhaps best demonstrates the effect of a restrictive case definition (23). Those authors identified multiple early cases of SARS-CoV-2 infection in Nottingham, UK, that, despite demonstrating symptoms consistent with COVID-19, did not meet case definition criteria used for diagnostic testing referral in place at the time because of lack of travel history or contact with an infected person. Genomic sequencing of these undetected cases revealed that most were acquired locally by community spread before widespread mitigation measures were adopted. These findings suggest that countries that used less sensitive case definitions, particularly at the start of the pandemic, might have grossly underestimated the true burden of disease, which affected decisions about the need for and timing of infection control measures. Changes in case definitions, both across and within countries, might also need to be considered when analyzing an epidemic curve for COVID-19 or other novel diseases.

The wide variation we found in suspected and probable case criteria and the complete omission of the probable case classification in some nations is of particular interest. WHO indicated that suspected and probable case definitions were revised to reflect increased knowledge of the clinical spectrum of COVID-19 signs and symptoms, especially the most common and predictive. These updates informed global and national surveillance because some symptoms have limited predictive value for surveillance purposes despite their frequent inclusion in case identification procedures (24–27). In its August 7, 2020, guidance, WHO delineated recommendations for handling each case classification. These recommendations included investigating suspected and probable cases for the presence of SARS-CoV-2 by using available laboratory tests, conducting contact tracing with persons with eligible exposure to probable and confirmed cases, and providing specific types of notifications within 24 hours of identifying probable and confirmed cases (8). This guidance also included a new request for countries to include counts of probable cases and confirmed cases in weekly aggregate reports.

WHO case definition guidance does not explicitly state a type of test for diagnostic confirmatory testing but references laboratory guidance that recommend nucleic acid amplification tests (NAATs), such as RT-PCR (28). Many countries might not have considered the laboratory guidance and used the WHO confirmed case definition verbatim. Indeed, we found that 7 countries did not specify a type of test for confirmatory testing. Results indicating some countries’ use of alternatives to NAAT as laboratory evidence is another key finding. Antigen tests, particularly point-of-care tests, have been promoted as a tool for early detection and preventing asymptomatic spread (10). However, their sensitivity is generally lower than NAATs, leading to false negatives (29). Antibody tests have typically been recommended as a surveillance assay rather than a standalone diagnostic tool (12,30). Despite the limitations of NAAT alternatives, their increasing availability in many areas and benefits such as lower overall cost, simplified logistics and supply chain management, and faster turnaround of results for rapid versions could explain their integration in some confirmed case definitions.

In all 25 countries, confirmed cases relied on diagnostic testing. Characterizing differences in eligibility for diagnostic testing across countries helps determine whether different persons are being diagnosed...
and designated as a confirmed case. For example, a country that requires symptoms and epidemiologic transmission to be eligible for diagnostic testing might have fewer cases detected than if they permitted testing to all persons in a country regardless of clinical or epidemiologic criteria. Early testing strategies targeted segments of the population believed to be at greatest risk for exposure to SARS-CoV-2. For example, national testing policy in Australia emphasized defining and targeting high-risk settings, such as residential care facilities or correctional facilities (31). In May 2020, the European Centre for Disease Prevention and Control expanded the pool of persons eligible for laboratory testing, resources permitting, to include asymptomatic persons in healthcare settings and long-term care facilities to identify potential sources of infection and protect vulnerable persons (14). WHO recommendations for laboratory testing also evolved over time and acknowledged that testing priorities would depend on intensity of transmission, number of cases, and laboratory capacity. On June 25, 2021, WHO released updated guidance that called on member states to create a national testing strategy that adapts to these changes and to implement public health actions that break transmission chains (32). Specific strategies for different SARS-CoV-2 transmission scenarios might include testing more persons than those who meet the latest suspected and probable case definitions, such as patients with unexpected clinical manifestations, asymptomatic contacts, and samples from existing sentinel surveillance sites. In addition, the guidance includes alternative testing strategies when laboratory capacity is low or overstretched.

Because of the large proportion of asymptomatic or mildly symptomatic COVID-19 cases, detecting both symptomatic and asymptomatic cases is necessary to ensure accurate case counts (33). Including asymptomatic cases also affects key epidemiologic metrics, such as incidence and case-fatality ratio. Although expansive testing criteria would increase the likelihood of detecting asymptomatic infections, this benefit should be weighed against the effort tracing and testing these eligible persons would have on the public health system (31). For example, broadening testing eligibility criteria might overload the healthcare system with persons who have low probability of infection or disease progression. Furthermore, many settings might not have adequate resources to test all eligible persons (33). Although WHO provides harmonious global testing criteria and case definitions, our findings suggest heterogeneity in how these aspects were adapted; it might be necessary to account for these deviations when comparing and collating COVID-19 case counts across countries.

The first limitation of our study is that, although the included studies represented ≈85% of reported cases globally, case definitions in the countries making up the remaining 15% of cases might differ. In addition, we chose to include the 25 countries with the highest number of reported cases, which might not represent the countries with the highest number of infections. Including countries on the basis of new infections from population-based serosurveillance or other sources merits future research. Second, although we identified suspected case definitions, confirmed case definitions, and testing criteria for most countries, we identified probable case definitions in only 16. This difference could be because of the lack of a probable case definition or its lack of availability in the public domain; regardless, the results of the probable case definition analyses might be less generalizable than the others. Third, we used Google Translate to translate definitions not in English in lieu of direct translation by native or bilingual speakers. Previous studies have used Google Translate for health-related text, including an analysis of national health agency mask guidance across multiple countries and regions during the COVID-19 pandemic (34). One study specifically compared the agreement between translations of abstracted data from published clinical trials between native speakers and Google Translate for 9 different languages and determined that agreement ranged from 85% to 97% (35). In our study, translation errors could have occurred for some languages and thus created discrepancies between the original policy intent and our interpretation of the translation. Fourth, our scope was limited to confirmed, probable, and suspected case definitions; other classifications, such as persons under investigation, might merit further research. Fifth, after extraction and analyses were completed, additional issues relating to case surveillance have emerged. These issues include cases amongst vaccinated persons, criteria for distinguishing a new case from an existing case (i.e., reinfection cases), as well as variants (17,36–39). Although these issues were not part of national case surveillance definitions, case surveillance amongst vaccinated persons can help inform stakeholders of changes in vaccine effectiveness, reinfection surveillance might provide further information on naturally acquired and vaccine-acquired immunity, whereas genomic surveillance could provide further insights on circulating strains. All three elements are vital to comprehensive national surveillance of COVID-19. Sixth, given the large number of possibilities, we chose not
to list every permutation of laboratory, clinical, and epidemiologic criteria for WHO and national suspected, probable, and confirmed case definitions. Finally, despite our analysis of each government’s policies, these policies might not be implemented equally in various settings and could change over time. To continue to build on the implications of this study, further research should determine the programmatic implications of less sensitive case definitions, such as whether misclassifying cases leads to outbreaks and onward population transmission.

Case surveillance remains the foundation for national COVID-19 surveillance and plays a vital role in ongoing situational awareness, clarifying the impact and effectiveness of vaccines and informing other public health and social measures. We observed marked heterogeneity in testing eligibility requirements among countries and how countries define COVID-19 cases. Specifically, we observed heterogeneity in eligible clinical symptoms for suspected case definitions, laboratory and diagnostic requirements for probable case definitions, and eligible laboratory assays for confirmed case definitions. Testing eligibility criteria varied from being restricted to populations with exposure and symptoms to all populations being eligible, regardless of exposure and symptoms. Collectively, these issues suggest that efforts to compare and collate COVID-19 case counts across countries require careful interpretation. Improved harmonization of case definitions across countries prospectively for COVID-19, and for other novel infectious diseases that might emerge, warrants consideration.

This article was preprinted at https://www.medrxiv.org/content/10.1101/2021.05.11.257047v1.

About the Author

Dr. Suthar is an epidemiologist in the Center for Global Health, Centers for Disease Control and Prevention. His research interests include infectious disease control, health system design, and digitization within the health sector. Ms. Schubert is a health scientist in the National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention. Her research interests include COVID-19 and other infectious disease surveillance and the spatial components of disease.

References

1. Suthar AB, Allen LG, Cifuentes S, Dye C, Nagata JM. Lessons learnt from implementation of the International Health Regulations: a systematic review. Bull World Health Organ. 2018;96:110–121E. https://doi.org/10.2471/BLT.16.189100

2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al.; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–33. https://doi.org/10.1056/NEJMoA2001017

3. National Health Commission of the People’s Republic of China. Update on the novel coronavirus pneumonia outbreak [cited 2020 Dec 13]. http://www.nhc.gov.cn/xcs/yqtb/list_gzbd.shtml

4. World Health Organization. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV) [cited 2020 Dec 13]. https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)

5. World Health Organization. Global surveillance for human infection with novel coronavirus (2019-nCoV): interim guidance, 31 January 2020 [cited 2020 Dec 13]. https://apps.who.int/iris/handle/10665/330857

6. World Health Organization. Global surveillance for COVID-19 caused by human infection with COVID-19 virus: interim guidance, 20 March 2020 [cited 2020 Dec 13]. https://apps.who.int/iris/handle/10665/331506

7. World Health Organization. Public health surveillance for COVID-19: interim guidance, 7 August 2020 [cited 2020 Dec 13]. https://apps.who.int/iris/handle/10665/333752

8. Koh D, Cunningham AC. Counting coronavirus disease 2019 (COVID-19) cases: case definitions, screened populations and testing techniques matter. Ann Acad Med Singapore. 2020;49:161–5. https://doi.org/10.47102/annals-acadmedsg.202038

9. Centers for Disease Control and Prevention. Overview of testing for SARS-CoV-2 (COVID-19) [cited 2021 Jan 29]. https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html

10. Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 test sensitivity—a strategy for containment. N Engl J Med. 2020;383:e120. https://doi.org/10.1056/NEJMp2005631

11. Gilbert M, Pullano G, Pinotti F, Valdano E, Poletto C, Boëlle P-Y, et al. Preparedness and vulnerability of African countries against importations of COVID-19: a modelling study. Lancet. 2020;395:871–7. https://doi.org/10.1016/S0140-6736(20)30411-6

12. Cheng MP, Papenburg J, Desjardins M, Kanjilal S, Quach C, Libman M, et al. Diagnostic testing for severe acute respiratory syndrome-related coronavirus 2: a narrative review. Ann Intern Med. 2020;172:726–34. https://doi.org/10.7326/M20-1301

13. Atsawarungkkit A, Yuan J, Kodama T, Cheng MT, Mansouri M, Han B, et al. Evolving global and national criteria for identifying a suspected case of COVID-19. J Int Med Res. 2020;48:300060520938943. https://doi.org/10.1177/0300060520938943

14. Peralta-Santos A. Assessment of COVID-19 surveillance case definitions and data reporting in the European Union. July 2020 [cited 2020 Dec 13]. https://www.europarl.europa.eu/RegData/etudes/BRAT/2020/652725/IPOL_BRI(2020)652725_EN.pdf

15. Tsang TK, Wu P, Lin Y, Lau EHY, Leung CM, Cowling BJ. Effect of changing case definitions for COVID-19 on the epidemic curve and transmission parameters in mainland China: a modelling study. Lancet Public Health. 2020;5:e289–96. https://doi.org/10.1016/S2468-2667(20)30089-X

16. World Health Organization. WHO coronavirus disease (COVID-19) dashboard [cited 2021 Jan 29]. https://covid19.who.int
17. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19) 2020 interim case definition, approved August 5, 2020 [cited 2020 Oct 13]. https://ncdc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2020-08-05

18. Ministry of Health and Social Protection, Government of Colombia. Optimization of testing, tracking and isolation program for the monitoring and follow-up of COVID-19 cases and contacts in Colombia [in Spanish]. 2020 Oct 19 [cited 2020 Nov 30]. https://www.minsaludgov.co/ Normatividad_Nuevo/Decreto%2001374%20de%202020.pdf

19. World Health Organization. Global surveillance for COVID-19 disease caused by human infection with novel coronavirus (COVID-19): interim guidance, 27 February 2020 [cited 2020 Dec 13]. https://apps.who.int/iris/handle/10665/331231

20. Teutsch SM. Considerations in planning a surveillance system. In: Lee LM, Teutsch SM, Thacker SB, St. Louis, ME, editors. Principles and practice of public health surveillance, 3rd ed. Oxford: Oxford University Press; 2010. p. 18–30.

21. Timen A, van Doornum GJJ, Schutten M, Conyn-van Spaendonck MA, van der Meer JW, Osterhaus AD, et al. Public health implications of using various case definitions in The Netherlands during the worldwide SARS outbreak. Clin Microbiol Infect. 2006;12:1214–20. https://doi.org/10.1111/j.1469-0691.2006.01552.x

22. Wu P, Hao X, Lau EHY, Wong JT, Leung KSM, Wu JT, et al. Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. Euro Surveill. 2020;25. https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000044

23. Chappell JG, Tsoleridis T, Clark G, Berry L, Holmes N, Moore C, et al.; on behalf of The Cog-UK Consortium. Retrospective screening of routine respiratory samples revealed undetected community transmission and missed intervention opportunities for SARS-CoV-2 in the United Kingdom. J Gen Virol. 2021;102:001595 https://doi.org/10.1099/jgv.0.001595

24. Dawson P, Rabold EM, Laws RL, Conners EE, Gharpure R, Yin S, et al. Loss of taste and smell as distinguishing symptoms of coronavirus disease 2019. Clin Infect Dis. 2021;72:682–5. https://doi.org/10.1093/cid/ciaa799

25. Haehner A, Draf J, Dräger S, de With K, Hummel T. Predictive value of sudden olfactory loss in the diagnosis of COVID-19. ORL J Otorhinolaryngol Relat Spec. 2020;82:175–80. https://doi.org/10.1159/000509143

26. Roland LT, Gurrola JG II, Loftus PA, Cheung SW, Chang JL. Smell and taste symptom-based predictive model for COVID-19 diagnosis. Int Forum Allergy Rhinol. 2020;10:832–8. https://doi.org/10.1002/1622602

27. Yamamoto-Moreno JA, Pineda-Aguilar C, Ruiz-Pérez S, Gortarez-Quintana GL, Ruiz-Dorado MA. Effectiveness of COVID-19 case definition in identifying SARS-CoV-2 infection in northern Mexico. Popul Med. 2020;2:1–8. https://doi.org/10.18332/popmed/127470

28. World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. 2020 [cited 2020 Dec 18]. https://www.who.int/publications/i/item/10665-331501

29. Centers for Disease Control and Prevention. Information for laboratories about coronavirus (COVID-19). 2020 Dec 18. https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html

30. Krajewska R, Golebiowska J, Makuch S, Mazur G, Agrawal S. Update on serologic testing in COVID-19. Clin Chim Acta. 2020;510:746–50. https://doi.org/10.1016/j.cca.2020.09.015

31. McArthur L, Sakthivel D, Ataide R, Englund JA, Lee MJ, Loeb M, et al. Infectious Diseases Society of America guidelines on the diagnosis of COVID-19. Clin Infect Dis. 2020;70:625–38. https://doi.org/10.4269/ajtmh.20-0564

32. World Health Organization. Recommendations for national SARS-CoV-2 testing strategies and diagnostic capacities: interim guidance, 25 June 2021 [cited 2021 Aug 29]. https://apps.who.int/iris/handle/10665/342002

33. Hanson KE, Caliendo AM, Arias CA, Englund JA, Lee MJ, Loeb M, et al. Infectious Diseases Society of America guidelines on the diagnosis of COVID-19. Clin Infect Dis. 2020;72:682–5. https://doi.org/10.1093/cid/ciaa760

34. Laestadius L, Wang Y, Ben Taleb Z, Kulan ME, Cho Y, Manganello J. Online national health agency mask guidance for the public in light of COVID-19: content analysis. JIMIR Public Health Surveillance. 2020;6:e19501. https://doi.org/10.2196/19501

35. Jackson JL, Kuriyama A, Anton A, Choi A, Fournier JP, Geier AK, et al. The accuracy of Google Translate for abstracting data from non-English-language trials for systematic reviews. Ann Intern Med. 2019;171:677–9. https://doi.org/10.7326/M19-0891

36. Pan American Health Organization/World Health Organization. Interim guidelines for detecting cases of reinfection by SARS-CoV-2 [cited 2020 Dec 18]. https://www.paho.org/en/documents/interim-guidelines-detecting-cases-reinfection-sars-cov-2

37. European Centre for Disease Prevention and Control. Reinfenction with SARS-CoV: considerations for public health response; 21 September 2020 [cited 2020 Dec 18]. https://www.ecdc.europa.eu/sites/default/files/documents/Re-infection-and-viral-shedding-threat-assessment-brief.pdf

38. World Health Organization. Guidance for surveillance of SARS-CoV-2 variants [cited 2021 Oct 18]. https://www.who.int/publications/i/item/WHO_2019-nCoV_surveillance_variants

39. World Health Organization. Guidance on conducting vaccine effectiveness evaluations in the setting of new SARS-CoV-2 variants [cited 2021 Oct 18]. https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccine-effectiveness-variants-2021

Address for correspondence: Amitabh Bipin Suthar, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop US1-2, Atlanta, GA 30329-4027, USA; email: icf4@cdc.gov
### Appendix

**Appendix Table 1.** Assessment of sources for COVID-19 case definition and testing criteria across 25 countries with the highest case counts, current as of January 1, 2021*

| Countries       | Case definition source (date)† | Testing criteria source (date)‡ |
|-----------------|--------------------------------|--------------------------------|
| WHO             | WHO (7) (2020 Aug 7)           | NA                             |
| Argentina       | Government (2) (2020 Sep 11)   | Government (3) (2020 Sep 23)   |
| Bangladesh      | Government (4) (2020 Nov 5)    | Government (20) (2020 Nov 5)   |
| Brazil          | Government (5) (2020 Aug 5)    | Government (20) (2020 Aug 5)   |
| Chile           | Government (6) (2020 Oct 1)    | Government (7) (2020 Nov 18)‡  |
| Colombia        | Government (8) (2020 Oct 19)   | Government (9) (2020 Oct)      |
| France          | ECDC (10) (2020 Dec 3)         | Government (11) (2020 Oct 19)‡ |
| Germany         | ECDC (10) (2020 Dec 3)         | Government (12) (2020 Dec 16)  |
| India           | Government (13) (2020 Jul 3)   | Government (14) (2020 Sep 4)   |
| Indonesia       | Government (15) (2020 Jul 13)  | Government (16) (2021 Jan 1)§  |
| Iran            | CDC contact (N. Farag, CDC, pers. comm., 2020 Sep 29)† | CDC contact (N. Farag, CDC, pers. comm., 2020 Sep 29)† |
| Iraq            | CDC contact (Y.Y. Majeed, CDC, pers. comm., 2020 Oct 2)† | CDC contact (Y.Y. Majeed, CDC, pers. comm., 2020 Oct 2)† |
| Israel          | CDC contact (H. Burke, CDC, pers. comm., 2020 Oct 7)† | Government (17) (2020 Dec 17)  |
| Italy           | ECDC (10) (2020 Dec 3)         | Government (18) (2020 Dec 3)   |
| Mexico          | Government (19) (2020 Aug 25)  | Government (21) (2020 Nov 11)  |
| Pakistan        | Government (22) (2020 Mar 27)  | Government (23) (2020 Dec 2)   |
| Peru            | Government (25) (2020 Jul 10)  | Government (26) (2020 Sep 30)  |
| Philippines     | Government (27) (2020 Nov 25)  | Government (28) (2020 Jul 6)   |
| Russia          | Government (29) (2020 Oct 26)  | Government (30) (2021 Jan 1)§** |
| Saudi Arabia    | Government (31) (2020 Oct)     | Government (31) (2020 Oct)     |
| South Africa    | Government (32) (2020 Aug 18)  | Government (33) (2020 Aug 16)  |
| Spain           | Government (34) (2020 Dec 18)  | Government (34) (2020 Dec 18)  |
| Turkey          | Government (35) (2020 Dec 7)   | Government (35) (2020 Dec 7)   |
| Ukraine         | Government (36) (2020 Mar 28)  | Government (37) (2021 Jan 1)§** |
| United Kingdom  | Government (38) (2020 Sep 28)  | Government (39) (2021 Jan 1)§** |
| United States   | Government (40) (2020 Aug 5)   | Government (41) (2020 Oct 21)  |

*CDC, Centers for Disease Control and Prevention; ECDC, European Centre for Disease Prevention and Control; NA, not applicable; WHO, World Health Organization.
†Date of Centers for Disease Control and Prevention contact communication.
‡Date the website was last updated.
§Date the source website was last verified in absence of website update date.
### Appendix Table 2: Full suspected case definitions of COVID-19 in countries with highest reported case counts

| Country    | Definition |
|------------|------------|
| WHO (reference) | 1. A person who meets the clinical AND epidemiologic criteria: Clinical Criteria: Acute onset of fever AND cough; OR Acute onset of ≥3 of the following signs or symptoms: fever, cough, general weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, anorexia/nausea/vomiting, diarrhea, altered mental status. Epidemiologic Criteria: Residing or working in an area with high risk for transmission of virus such as closed residential settings or humanitarian settings such as camp and camp-like settings for displaced persons, anytime within the 14 days before symptom onset; OR Residing or travel to an area with community transmission anytime within the 14 days before symptom onset; OR Working in any healthcare setting, including within health facilities or within the community, anytime within the 14 days before symptom onset. 2. A patient with severe acute respiratory illness: acute respiratory infection with history of fever or measured fever of ≥38°C and cough, with onset within the last 10 days and requiring hospitalization. |
| Iraq†      | 1. A patient with acute respiratory illness (fever and ≥1 sign/symptom of respiratory disease, such as cough or shortness of breath) AND a history of travel to or residence in a location reporting community transmission of COVID-19 during the 14 days before symptom onset. 2. A patient with any acute respiratory illness AND having been in contact with a confirmed or probable person with COVID-19 (see definition of contact) in the 14 days before symptom onset. 3. A patient with severe acute respiratory illness (fever and ≥1 sign/symptom of respiratory disease, such as cough or shortness of breath AND requiring hospitalization) AND in the absence of an alternative diagnosis that fully explains the clinical manifestation. |
| Bangladesh† | 1. Individual with acute respiratory condition, characterized by at ≥2 of the following signs and symptoms: fever (even if referred), chills, sore throat, headache, cough, runny nose, olfactory disorders or taste disorders. In children, nasal obstruction is also considered in addition to the previous symptoms, in the absence of another specific diagnosis. In the elderly, specific aggravation criteria such as syncope, mental confusion, excessive sleepiness, irritability, and inappetence should also be considered. If COVID-19 is suspected, fever might be absent and gastrointestinal symptoms (diarrhea) might be present. 2. Individual with Influenza-like illness who has dyspnea or respiratory discomfort OR Persistent pressure in the chest OR O2 saturation <95% in room air OR Bluish color of the lips or face. In children, in addition to the previous items, flapping of the nose, cyanosis, intercostal circulation, dehydration, and lack of appetite. |
| Philippines† | 1. A person who meets the clinical AND epidemiologic criteria: Clinical Criteria: Acute onset of fever AND cough; OR Acute onset of ≥3 of the following signs or symptoms: fever, cough, general weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, anorexia/nausea/vomiting, diarrhea, altered mental status. Epidemiologic Criteria: Residing or working in an area with high risk for transmission of virus such as closed residential settings or humanitarian settings such as camp and camp-like settings for displaced persons, anytime within the 14 days before symptom onset; OR Residing or travel to an area with community transmission anytime within the 14 days before symptom onset; OR Working in any healthcare setting, including within health facilities or within the community, anytime within the 14 days before symptom onset. 2. A patient with severe acute respiratory illness: acute respiratory infection with history of fever or measured fever of ≥38°C and cough, with onset within the last 10 days and requiring hospitalization. |
| India      | 1. A person meeting clinical criteria: 1. Individual with acute respiratory condition, characterized by at ≥2 of the following signs and symptoms: fever (even if referred), chills, sore throat, headache, cough, runny nose, olfactory disorders or taste disorders. In children, nasal obstruction is also considered in addition to the previous symptoms, in the absence of another specific diagnosis. In the elderly, specific aggravation criteria such as syncope, mental confusion, excessive sleepiness, irritability, and inappetence should also be considered. If COVID-19 is suspected, fever might be absent and gastrointestinal symptoms (diarrhea) might be present. 2. Individual with Influenza-like illness who has dyspnea or respiratory discomfort OR Persistent pressure in the chest OR O2 saturation <95% in room air OR Bluish color of the lips or face. In children, in addition to the previous items, flapping of the nose, cyanosis, intercostal circulation, dehydration, and lack of appetite. |
| Pakistan   | 1. A patient who meets the clinical AND epidemiologic criteria: Clinical Criteria: Acute onset of fever AND cough; OR Acute onset of ≥3 of the following signs or symptoms: fever, cough, general weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, anorexia/nausea/vomiting, diarrhea, altered mental status. Epidemiologic Criteria: Residing or working in an area with high risk for transmission of virus such as closed residential settings or humanitarian settings such as camp and camp-like settings for displaced persons, anytime within the 14 days before symptom onset; OR Residing or travel to an area with community transmission anytime within the 14 days before symptom onset; OR Working in any healthcare setting, including within health facilities or within the community, anytime within the 14 days before symptom onset. 2. A patient with severe acute respiratory illness: acute respiratory infection with history of fever or measured fever of ≥38°C and cough, with onset within the last 10 days and requiring hospitalization. |
| United States | Meets supportive laboratory evidence with no previous history of being a confirmed or probable case. Supportive laboratory evidence: Detection of specific antibody in serum, plasma, or whole blood. Detection of specific antigen by immunochromatography in an autopsy specimen. |
| Italy‡§    | Any person meeting clinical criteria: ≥1 of the following symptoms: cough, fever, shortness of breath, or sudden onset of anosmia, ageusia, or dysgeusia. Additional less specific symptoms include headache, chills, muscle pain, fatigue, vomiting, or diarrhea. |
| Germany‡§  | Any person meeting clinical criteria: ≥1 of the following symptoms: cough, fever, shortness of breath, or sudden onset of anosmia, ageusia, or dysgeusia. Additional less specific symptoms include headache, chills, muscle pain, fatigue, vomiting, or diarrhea. |
| France‡§   | Any person meeting clinical criteria: ≥1 of the following symptoms: cough, fever, shortness of breath, or sudden onset of anosmia, ageusia, or dysgeusia. Additional less specific symptoms include headache, chills, muscle pain, fatigue, vomiting, or diarrhea. |
| Brazil     | Clinical manifestations of acute respiratory infection: temperature >37.5°C and ≥1 of the following: cough (dry or with scanty sputum), shortness of breath, feeling of congestion in the chest, satiety blood oxygen according to pulse oximetry (SpO2) <95%, sore throat, nasal congestion or mild rhinorrhea, impaired or loss of smell (hyposmia or anosmia), loss of taste (dysgeusia), conjunctivitis, weakness, muscle pain, headache, vomiting, diarrhea, or skin rash in the absence of other known causes, which explain the clinical picture regardless of the epidemiologic anamnesis. |
| Russia     | Person with exposure because of having been in a place with community transmission or outbreak or contact with probable cases, and with respiratory OR nonrespiratory clinical manifestations of COVID-19 of any severity, clinical laboratory or radiologic findings belonging to groups of risk factors or vulnerability. Also, asymptomatic persons with exposure to probable or confirmed COVID-19 case-patients. Respiratory clinical manifestations: fever >38°C, cough, fatigue, expectoration, shortness of breath or dyspnea, sore throat, rhinorrhea, SpO2 <93%. Nonrespiratory clinical manifestations: anosmia, hypoxia, ageusia, dysgeusia, diarrhea, anorexia, nausea and vomiting, abdominal pain or discomfort, acute conjunctivitis, seizures, vertigo, headache, myalgia, skeletal muscle injuries, altered consciousness, acute cerebrovascular disease, ataxia, seizures, meningencephalitis, Guillain-Barre syndrome, mental status disorders, hepatic compromise due to elevatedaminotransferases, erythematous rash, hive rash, vesicles, acral ischemia, unilateral transient livedo reticularis, acute cardiac injury, heart failure arrhythmia, shock, acute myocarditis, chest tightness, acute kidney injury, urinary symptoms or cystitis, coagulation disorders, thrombotic events, antiphospholipid antibodies, hearing loss, or hearing discomfort. Clinical laboratory and radiologic findings: laboratory and nonetiologic clinical diagnostic tests: Albumin Decrease (81%), CRP increase (79%) (MIS-C 94%), LDH increase (99.3%), Thrombocytosis (61%), Lymphopenia (57.5%, 25%, 56.5%), Interleukin-6 increase (56%), AST Increase (37%), Leukopenia (28%, 25%), Leukocytosis (18.3%), Neutrophilia (MIS-C 83%), Thrombocytopenia (13%, 16.4%–32.3%), Increase in D-dimer, Ferritin, Decrease in T3 and T4 Troponin T (MIS-C 68%), pro BNP (MIS-C 77%). Pulmonary radiological findings: Bilateral commitment (81%), Consolidation (73.5%), Ground Glass Opacity (73.5%), Abnormal echocardiogram (MIS-C 59%, 63%). Factors of vulnerability: healthcare workers, workers who serve in high volumes of public work in social protection, workers with high mobility because of occupational activity, and internal Colombian migrants. |
| Colombia   | Person with acute respiratory infection experiencing cough or pain from throat and ≥1 of the following signs / symptoms: general discomfort, fever, headache, difficulty breathing, nasal congestion. |
| Peru       | Person with acute respiratory infection experiencing cough or pain from throat and ≥1 of the following signs / symptoms: general discomfort, fever, headache, difficulty breathing, nasal congestion. |
| Argentina  | Person with acute respiratory infection experiencing cough or pain from throat and ≥1 of the following signs / symptoms: general discomfort, fever, headache, difficulty breathing, nasal congestion. |
| Country       | Definition                                                                                                                                 |
|--------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| Spain        | Anyone with a clinical picture of acute respiratory infection of sudden onset of any severity that occurs, among others, with fever, cough, or shortness of breath. Other symptoms such as odynophagia, anosmia, ageusia, muscle pain, diarrea, chest pain, or headache, among others, might also be considered symptoms of suspected SARS-CoV-2 infection according to clinical judgment. |
| Mexico       | Person of any age who has had ≥1 of the following signs and symptoms in the last 10 days: cough, fever, dyspnea (serious condition), or headache. In children <5 years of age, irritability can replace headache. Accompanied by ≥1 of the following minor signs or symptoms: myalgia, arthralgias, odynophagia, chills, chest pain, rhinorrhea, anosmia, dyseuasia, or conjunctivitis. |
| Saudi Arabia | Any person presenting with an acute (<10 days) respiratory tract infection or other clinical illness compatible with COVID-19, or an asymptomatic person who is a close contact of a confirmed case-patient. Symptoms include ANY of the following respiratory symptoms: cough, sore throat, shortness of breath, anosmia (loss of sense of smell), or dysgeusia (alteration of the sense of taste), with or without other symptoms (which might include fever, weakness, myalgia, or diarrhea). |
| United Kingdom | New continuous cough or temperature ≥37.8°C or loss of or change in normal sense of smell (anosmia) or taste (ageusia). |
| Iran         | 1. Acute onset of fever OR acute onset of ILI/ARI symptoms or nausea and vomiting AND epidemiologic criteria (residing/travel to high-risk settings or community transmission or health facilities within 14 days of symptom onset). 2. Severe acute respiratory infection. |
| Chile        | 1. Patient presenting an acute picture with ≥2 of the symptoms compatible with COVID-19: fever (>37.8°C), cough, dyspnea, chest pain, odynophagia, myalgia, chills, headache, diarrhea, or sudden loss or decrease of smell (anosmia or hyposmia) or taste (ageusia or dysgeusia). 2. Patient with severe acute respiratory infection requiring hospitalization. |
| Turkey       | 1. At least 1 of the following signs and symptoms: fever, cough, shortness of breath, sore throat, headache, muscle aches, loss of taste and smell, diarrhea AND the clinical picture cannot be explained by another cause or disease AND 1 of the following within 14 days before the onset of symptoms: person or close contact has history of being in a high-risk area for the disease or person has confirmed contact with a COVID-19 case-patient. 2. At least 1 of the signs and symptoms of fever and severe acute respiratory infection (SARI) (cough and respiratory distress), requiring hospitalization, and the clinical picture cannot be explained by another cause or disease. SARI: The need for hospitalization because of fever, cough and dyspnea, tachypnea, hypoxemia, hypotension, diffuse radiological findings on lung imaging, and change in consciousness in a patient with acute respiratory tract infection that developed in the last 14 days. 3. Combination of ≥2 of the following signs and symptoms: fever, cough, shortness of breath, sore throat, headache, muscle aches, loss of taste and smell or diarrhea, and this situation cannot be explained by another cause or disease. |
| Indonesia    | 1. A person who has 1 of the following criteria: persons with acute respiratory infections (ARI) (namely fever (≥38°C) or a history of fever and accompanied by any of the symptoms or signs of respiratory disease such as cough, shortness of breath, sore throat, runny nose, pneumonia from mild to severe AND in the last 14 days before symptoms appeared, had a history of travel to or lives in a country or territory of Indonesia reporting local transmissions. 2. People with any of the symptoms or signs of ARI AND in the last 14 days before symptoms develop had a history of contact with a confirmed or probable COVID-19 case. 3. People with severe ARD or severe pneumonia requiring hospitalization AND no other cause based on a convincing clinical picture. |
| Israel       | Israel does not have official surveillance case definitions; persons are considered suspect on the basis of contact with confirmed cases determined by digital surveillance of cellphones. |
| Ukraine      | 1. A patient with acute respiratory illness (sudden onset, fever, and ≥1 of the following symptoms: cough or difficulty breathing), regardless of the need for hospitalization, and who 14 days before the onset of symptoms meets ≥1 of the following epidemiologic criteria: contact with a confirmed or probable case of COVID-19 or visited or resided in a country or region with local transmission of the virus in the community according to WHO situation reports. 2. Patient with severe acute respiratory disease (body temperature ≥38°C and ≥1 of the following symptoms: cough or difficulty breathing) requiring hospitalization and the absence of other reasons that fully explain the clinical picture. |

ARD, acute respiratory distress; ARI, acute respiratory infection; AST, Aspartate Aminotransferase; BNP, B-type natriuretic peptide; COVID-19, coronavirus disease; CRP, C-reactive protein; ILI, influenza-like illness; LDH, Lactate Dehydrogenase; MIS-C, Multisystem Inflammatory Syndrome-children; SARI, severe acute respiratory infection; SARS-CoV-2, severe acute respiratory infection coronavirus 2; SpO2, blood oxygen saturation; WHO, World Health Organization.  
†World Health Organization definition.  
‡These countries use a possible case definition in place of a suspected case definition.  
§European Centre for Disease Prevention and Control definition.
### Diagnostic testing

| Country | Laboratory evidence | Cough | Fever | SARI | Labored breathing | Headache | Muscle pain | Sore throat or odynophagia | Chest pain or congestion | Nonlytmic nose or nasal congestion | Loss of taste or smell | Diarrhea | Nausea or vomiting | Joint pain | Chills | Rash | SPO₂ Level | Conjunctivitis | Fatigue or weakness | Travel history | Hospitalized | Confirmed contact | Healthcare employee | Diagnostic clinical or EPI† |
|---------|---------------------|-------|-------|------|------------------|----------|-------------|--------------------------|-------------------------|---------------------------|----------------------|----------|------------------|----------|-------|------|------------|-----------------|------------------|---------------|--------------|-------------------|-------------------|------------------|
| Argentina | X X X X X X X X | X X X X | | | | | | | | | | | | | | | | | | |
| Bangladesh | X X X X X X X X | | | | | | | | | | | | | | | | | | | |
| Brazil | X X X X X X X X | | | | | | | | | | | | | | | | | | | |
| Chile | X X X X X X X X | | | | | | | | | | | | | | | | | | | |
| Colombia | X X X X X X X X | X X X X | | | | | | | | | | | | | | | | | | |
| France | X X X X X X X X | | | | | | | | | | | | | | | | | | | |
| Germany | X X X X X X X X | | | | | | | | | | | | | | | | | | | |
| India | X X X X X X | | | | | | | | | | | | | | | | | | | |
| Indonesia | X X X X | X | | | | | | | | | | | | | | | | | | |
| Iran | X X X | | | | | | | | | | | | | | | | | | | |
| Iraq | X X X X X X X X | X X X X | | | | | | | | | | | | | | | | | | |
| Israel | X X X X X X X X | | | | | | | | | | | | | | | | | | | |
| Italy | X X X X X X | X X X X | | | | | | | | | | | | | | | | | | |
| Mexico | X X X X X X X X | | | | | | | | | | | | | | | | | | | |
| Pakistan | X X X X | | | | | | | | | | | | | | | | | | | |
| Peru | X X X X | | | | | | | | | | | | | | | | | | | |
| Philippines | X X X X X X X | X X X X | | | | | | | | | | | | | | | | | | |
| Russia | X X X X X X | X X X X | | | | | | | | | | | | | | | | | | |
| Saudi Arabia | X X X X X X X X | X X X X | | | | | | | | | | | | | | | | | | |
| South Africa | X X X X | X X X | | | | | | | | | | | | | | | | | | |
| Spain | X X X X X X X | X X X | | | | | | | | | | | | | | | | | | |
| Turkey | X X X X X X | X X | | | | | | | | | | | | | | | | | | |
| Ukraine | X X X X X X | | | | | | | | | | | | | | | | | | | |
| United Kingdom | X X X | | | | | | | | | | | | | | | | | | | |
| United States | X | X X | | | | | | | | | | | | | | | | | | |

**Appendix Table 3.** Full suspected COVID-19 case definition criteria across 25 countries with the highest case counts, current as of January 1, 2021‡

| No. countries including criterion | 2 | 21 | 23 | 16 | 21 | 15 | 14 | 12 | 4 | 10 | 14 | 15 | 11 | 2 | 6 | 2 | 3 | 3 | 10 | 11 | 10 | 10 | 6 | 7 |
|----------------------------------|---|-----|-----|-----|-----|-----|-----|-----|---|----|-----|-----|----|---|---|---|---|---|----|----|----|---|---|---|---|
| % of countries†† | 8% | 84% | 92% | 64% | 84% | 60% | 56% | 48% | 16% | 40% | 56% | 60% | 44% | 8% | 24% | 8% | 12% | 12% | 40% | 44% | 40% | 40% | 24% | 28% |

*Indicates the criterion was sufficient for, or a potential component of, the suspected case definition requirement(s). Full suspected case definitions can be found in Appendix Table 2. SARI, severe acute respiratory infection; SPO₂, blood oxygen saturation; WHO, World Health Organization.
†Refer to suspected case definition for applicable country (Appendix Table 2).
‡World Health Organization definition (updated August 2020).
§European Centre for Disease Prevention and Control definition.
¶These countries consider these definitions as possible not suspected cases; because of the comparability between possible and suspected, we treated these definitions as a suspected definition.
©World Health Organization definition (updated March 2020).
***Israel does not have official surveillance case definitions; persons are considered suspected on the basis of contact with confirmed cases determined by digital surveillance of cellphones.
++Denominator is 24 countries with suspected case definition.
### Appendix Table 4. Probable case definitions of COVID-19 in countries with highest reported case counts*

| Country | Definition |
|---------|------------|
| Chile  | 1. A patient who meets clinical criteria AND is a contact of a probable or confirmed case, or epidemiologically linked to a cluster with >1 confirmed case. 2. A suspected case with chest imaging showing findings suggestive of COVID-19. Typical chest imaging findings suggestive of COVID-19 include the following chest radiography: hazy opacities, often rounded in morphology, with peripheral and lower lung distribution; chest CT: multiple bilateral ground glass opacities, often rounded in morphology, with peripheral and lower lung distribution; lung ultrasound: thickened pleural lines, B lines (multifocal, discrete, or confluent), consolidative patterns with or without air bronchograms. 3. A person with recent onset of anosmia (loss of smell) or ageusia (loss of taste) in the absence of any other identified cause. 4. Death, not otherwise explained, in an adult with respiratory distress preceding death AND was a contact of a probable or confirmed case or epidemiologically linked to a cluster with >1 confirmed case. |
| Iran  | No probable case definition. |
| Bangladesh†  | No probable case definition. |
| Philippines‡ | No probable case definition. |
| India  | 1. A suspected case for whom testing for the COVID-19 virus is inconclusive. 2. A suspected case for whom testing could not be performed for any reason. |
| Pakistan  | No probable case definition. |
| USA  | 1. Meets clinical criteria AND epidemiologic evidence with no confirmatory laboratory testing performed for COVID-19. 2. Meets presumptive laboratory evidence (detection of SARS-CoV-2 by antigen test in a respiratory specimen). 3. Meets vital records criteria with no confirmatory laboratory evidence. Clinical criteria: ≥2 of the following symptoms: fever (measured or subjective), chills, rigors, myalgia, headache, sore throat, nausea or vomiting, diarrhea, fatigue, congestion, or runny nose OR ≥1 of the following symptoms: cough, shortness of breath, difficulty breathing, new olfactory disorder, new taste disorder OR severe respiratory illness with ≥1 of the following: clinical or radiographic evidence of pneumonia, acute respiratory distress syndrome (ARDS). Epidemiologic criteria: ≥1 of the following exposures in the previous 14 days: close contact with a confirmed or probable case of COVID-19 OR member of a risk cohort as defined by public health authorities during an outbreak. |
| Italy‡  | Any person meeting clinical criteria (≥1 of the following symptoms: cough, fever, shortness of breath, sudden onset of anosmia, ageusia or dysgeusia) with epidemiologic link (close contact with confirmed case within 14 days before onset or having been a resident or staff in an institution with ongoing transmission within 14 days before onset) OR any person meeting diagnostic criteria (radiological evidence showing lesions compatible with COVID-19). |
| Germany‡  | No probable case definition. |
| France‡  | No probable case definition. |
| Brazil  | Same as suspected case AND ≥1 of the epidemiologic signs is present: return from a foreign trip 14 days before the onset of symptoms; having close contact in the last 14 days with a person under monitoring for COVID-19 who subsequently fell ill; having close contact in the last 14 days with a person who has a laboratory-confirmed diagnosis of COVID-19; availability of professional contacts with persons who have been identified as suspected or confirmed case of COVID-19. |
| Russia  | No probable case definition. |
| Colombia  | Person with any type of individual or multiple exposure to confirmed cases and with respiratory or nonrespiratory clinical manifestations of COVID-19, of any severity, and clinical or radiological laboratory findings. It also includes the person with doubtful etiologic laboratory results (RT-PCR) or laboratory testing is not feasible for some reason. Respiratory clinical manifestations: fever >38°C, cough, fatigue, expectoration, shortness of breath or dyspnea, sore throat, rhinorrhea, SpO2 <93%. Nonrespiratory clinical manifestations: anorexia, hyposmia, ageusia, dysgeusia, diarrhea, anorexia, nausea or vomiting, abdominal pain; or discomfort, acute conjunctivitis, seizures, vertigo, headache, myalgia, skeletal muscle injuries, altered consciousness, acute cerebrovascular disease, ataxia, seizures, meningencephalitis, Guillain-Barre syndrome, mental status disorders, hepatic function abnormalities due to elevated aminotransferases, erythematous rash, hive rash, vesicles, acral ischemia, unilateral transient livedo reticularis, acute cardiac injury, heart failure arrhythmia, shock, acute myocarditis, chest tightness, acute kidney injury, urinary symptoms or cystitis, coagulation disorders, thrombotic events, antiphospholipid antibodies, hearing loss or hearing discomfort. |
| Peru  | No probable case definition. |
| Argentina  | No probable case definition. |
| Spain  | 1. Person with severe acute respiratory infection with clinical and radiological symptoms compatible with COVID-19 and negative diagnostic test results, or suspected cases with inconclusive diagnostic test. 2. Cases with high clinical-epidemiologic suspicion with repeatedly negative diagnostic test (>1 PCR) and positive serologic testing for SARS-CoV-2 performed by high-throughput serologic techniques. |
| Mexico  | No probable case definition. |
| South Africa  | No probable case definition. |
| United Kingdom  | No probable case definition. |
| Iran  | 1. Suspected case AND close contact with probable or confirmed case. 2. Suspected case AND positive imaging. 3. Acute onset of anosmia or ageusia without identified cause. 4. Death of a suspected case. |
| Chile  | 1. Probable case by laboratory result: patient who meets the definition of a suspected case in whom the PCR result is indeterminate or who has a positive antigenic test for SARS-CoV-2. 2. Probable case because of epidemiologic link: person who has been in close contact with a confirmed case and develops fever (axillary temperature ≥37.8°C) or ≥2 symptoms compatible with COVID-19 within 14 days of contact. The probable case because of an epidemiologic link does not require an RT-PCR test for SARS-CoV-2. If for any reason, a probable case-patient undergoes a confirmatory examination and it is positive, it will be considered a confirmed case. On the contrary, if the result is negative or indeterminate, it will continue to be considered a probable case. 3. Probable case by imaging: suspicious case with negative RT-PCR result for SARS-CoV-2 but with a chest CT scan with characteristic images of COVID-19 according to the radiological report. 4. Probable case because of symptoms: person with sudden and complete loss of smell (anosmia) or taste (ageusia) without an explanation. |
| Country      | Definition                                                                                                                                 |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------|
| Saudi Arabia| No probable case definition.                                                                                                                |
| Turkey      | No probable case definition.                                                                                                                |
| Philippines | 1. Suspected case whose testing for COVID-19 is inconclusive. 2. Suspected case who tested positive for COVID-19 but whose test was not conducted in a national or subnational reference laboratory or officially accredited laboratory for COVID-19 confirmatory testing. 3. Suspected case who died without undergoing any confirmatory testing. |
| Indonesia   | 1. Suspected cases with SARI. 2. Died with a convincing clinical picture of COVID-19 AND no RT-PCR laboratory results.                     |
| Israel      | Israel does not have official surveillance case definitions; persons are considered suspected case-patients on the basis of contact with confirmed cases determined by digital surveillance of cellphones. |
| Ukraine     | A suspected case for whom laboratory testing cannot be unambiguously interpreted.                                                            |

*COVID-19, coronavirus disease; CT, computed tomography; RT-PCR, reverse transcription PCR; SARI, severe acute respiratory infection; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
†World Health Organization definition.
‡European Centre for Disease Prevention and Control definition.
### Appendix Table 5. Full probable COVID-19 case definition criteria across 25 countries with the highest case counts, current as of January 1, 2021*

| Country          | Diagnostic testing | Clinical symptoms | Epidemiologic criteria | Other |
|------------------|--------------------|-------------------|------------------------|-------|
|                  | Inconclusive test  |                  |                        |       |
|                  | Antigen test       | Cough             | Fever                  |       |
|                  | Antibody test      | SARI              | Laborad breathing      |       |
|                  | Radiographic imagery | Muscle pain     | Headache               |       |
|                  |                    |                   | Chest pain or chest congestion |     |
|                  |                    |                   | Sore throat or oropharyngia |    |
|                  |                    |                   | Loss of taste or smell  |       |
|                  |                    |                   | Diarrhea               |       |
|                  |                    |                   | Nausea or vomiting      |       |
|                  |                    |                   | Chills                 |       |
|                  |                    |                   | Rash                   |       |
|                  |                    |                   | Conjunctivitis         |       |
|                  |                    |                   | Fatigue or weakness    |       |
|                  |                    |                   | Travel history         |       |
|                  |                    |                   | Hospitalized           |       |
|                  |                    |                   | Confirmed contact      |       |
| WHO definition   | X                  | X                 | X                      | X     |
| (Reference)      |                    |                   |                        |       |
| Bangladesh       | X                  | X                 | X                      | X     |
|                  |                    |                   |                        |       |
| Brazil           | X                  | X                 | X                      | X     |
|                  |                    |                   |                        |       |
| Colombia         | X                  | X                 | X                      | X     |
|                  |                    |                   |                        |       |
| France           | X                  | X                 | X                      | X     |
|                  |                    |                   |                        |       |
| Germany          | X                  | X                 | X                      | X     |
|                  |                    |                   |                        |       |
| India            | X                  | X                 | X                      | X     |
|                  |                    |                   |                        |       |
| Indonesia        | X                  | X                 | X                      | X     |
|                  |                    |                   |                        |       |
| Iran             | X                  | X                 | X                      | X     |
|                  |                    |                   |                        |       |
| Iraq             | X                  | X                 | X                      | X     |
|                  |                    |                   |                        |       |
| Israel           | X                  | X                 | X                      | X     |
|                  |                    |                   |                        |       |
| Italy            | X                  | X                 | X                      | X     |
|                  |                    |                   |                        |       |
| Mexico           | X                  | X                 | X                      | X     |
|                  |                    |                   |                        |       |
| Pakistan         | X                  | X                 | X                      | X     |
|                  |                    |                   |                        |       |
| Peru             | X                  | X                 | X                      | X     |
| Philippines      | X                  | X                 | X                      | X     |
|                  |                    |                   |                        |       |
| Russia           | X                  | X                 | X                      | X     |
|                  |                    |                   |                        |       |
| Saudi Arabia     | X                  | X                 | X                      | X     |
|                  |                    |                   |                        |       |
| South Africa     | X                  | X                 | X                      | X     |
| Spain            | X                  | X                 | X                      | X     |
| Turkey           | X                  | X                 | X                      | X     |
| Ukraine          | X                  | X                 | X                      | X     |
| United Kingdom   | X                  | X                 | X                      | X     |
| United States    | X                  | X                 | X                      | X     |
| Country Totals   | 6                  | 2                 | 10                     | 14    |
| % of countries   | 38%                | 13%               | 0%                     | 63%   |

*Indicates the criterion was sufficient for, or a potential component of, the probable case definition requirement(s). Full probable case definitions can be found in Appendix Table 4. SARI, severe acute respiratory infection; SpO2, blood oxygen saturation; WHO, World Health Organization.

†Refer to probable case definition for applicable country (Appendix Table 4).

§World Health Organization definition (updated August 2020).

§European Centre for Disease Prevention and Control definition.

¶World Health Organization definition (updated March 2020).

#Denominator is 16 countries with probable case definition.
| **Country** | **Definition** |
|------------|---------------|
| **WHO**    | A person with laboratory confirmation of 2019-nCoV infection, irrespective of clinical signs and symptoms. |
| **Iraq†**  | 1. Any person, irrespective of presence or absence of clinical signs and symptoms, who was laboratory confirmed for COVID-19 in a test conducted at the national reference laboratory, a subnational reference laboratory, or Department of Health-licensed COVID-19 testing laboratory. 2. Any suspected or probable COVID-19 cases who tested positive using antigen tests in areas without breaks or in remote settings where RT-PCR is not immediately available; provided that the antigen tests satisfy the recommended minimum regulatory, technical, and operational specifications set by the Health Technology Assessment. |
| **Bangladesh†** | A person who meets the definition of a suspected case in which the specific test for SARS-CoV-2 was positive (RT-PCR). |
| **Philippines†** | 1. Case of ILI or SARI with clinical confirmation associated with anosmia (olfactory dysfunction) or ageusia (gustatory dysfunction) without any other previous cause. 2. Case of ILI or SARI with history of close or home contact, in the 14 days before appearance of signs and symptoms with confirmed case. 3. Case of ILI or SARI or death due to SARS that could not be confirmed by laboratory criteria AND that presents ≥1 of the following tomographic changes: peripheral, bilateral, frosted glass opacity, with or without consolidation or visible intraalobular lines ("paving"), or multifocal matte glass opacity with rounded morphology with or without consolidation or visible intraalobular lines ("paving"), or reverse halo sign or other findings of organizing pneumonia (seen later in the disease). 4. Case of ILI or SARI with test of positive result for SARS-CoV-2 performed by the RT-PCR method in real time or REAGENT result for IgM, IgA and / or IgG performed by the following methods: ELISA; immunochromatography (rapid test) for antibody detection; ECLIA; Or Antigen Search: reagent result for SARS-CoV-2 by the Immunochromatography method for antigen detection. 5. Asymptomatic persons with 1 of the following results: positive result for SARS-CoV-2 performed by the RT-PCR method in real time or immunological reagent result for IGM and/or IGA performed by the following methods: ELISA or immunochromatography (rapid test) for antibody detection. |
| **India**  | A person with laboratory confirmation of 2019-nCoV infection, irrespective of clinical signs and symptoms. |
| **Pakistan** | A person who meets laboratory criteria (detection of SARS-CoV-2 nucleic acid or antigen in a clinical specimen). |
| **USA**    | Meets confirmatory laboratory evidence (detection of SARS-CoV-2 RNA in a clinical specimen using a molecular amplification detection test). |
| **Italy‡** | Any person meeting laboratory criteria (detection of SARS-CoV-2 nucleic acid or antigen in a clinical specimen). |
| **Germany‡** | Any person meeting laboratory criteria (detection of SARS-CoV-2 nucleic acid or antigen in a clinical specimen). |
| **France‡** | Any person meeting laboratory criteria (detection of SARS-CoV-2 nucleic acid or antigen in a clinical specimen). |
| **Brazil** | 1. A positive laboratory test result for the presence of RNA SARS-CoV-2 using NAAT or SARS-CoV-2 antigen using immunochromatographic analysis regardless of clinical manifestations.2. Positive result for IgA, IgM and / or IgG antibodies in patients with a clinically confirmed COVID-19 infection. |
| **Russia** | 1. Person who meets clinical criteria for a suspected case and has a laboratory-confirmed diagnosis. May change according to new evidence) with positive results of active infection by the SARS-CoV-2 virus regardless of the presence or absence of clinical criteria, since the tests can be performed in asymptomatic, suspected or probable patients, with different prioritization. |
| **Colombia** | Person with laboratory (RT-PCR for SARS-CoV-2 (MIS-C 59%, 13%–69%) or Antigen detection test (alternative diagnosis). |
| Country   | Definition                                                                 |
|----------|----------------------------------------------------------------------------|
| Turkey   | Cases in which SARS-CoV-2 is detected by molecular methods among the cases matching the possible case definition. |
| Indonesia| A person who has tested positive for the COVID-19 virus proven by the RT-PCR laboratory examination. Confirmation cases are divided into: confirmation case with symptoms (symptomatic), confirmation cases without symptoms (asymptomatic). |
| Israel   | Positive COVID-19 test result.                                             |
| Ukraine  | A person with a laboratory-confirmed COVID-19 disease, regardless of clinical signs and symptoms. |

*COVID-19, coronavirus disease; ECLIA, electrochemiluminescence immunoassay; ILI, influenza-like illness; MIS-C, multisystem inflammatory syndrome–children; NAAT, nucleic acid amplification technique; RT-PCR, reverse transcription PCR; SARS, severe acute respiratory syndrome; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
†World Health Organization definition.
‡European Centre for Disease Prevention and Control definition.
### Appendix Table 7. Full confirmed COVID-19 case definition criteria across 25 countries with the highest case counts, current as of January 1, 2021*

| Country          | Diagnostic testing | Clinical symptoms | Epidemiologic criteria | Other† |
|------------------|--------------------|-------------------|------------------------|--------|
|                  | PCR test           | Antigen test      | Antibody test (nonspecified) | Radiographic imagery | Meet suspected case definition | Cough | Fever | SARI | Loss of taste or smell | Travel history | Hospitalized | Confirmed contact | Diagnostic, clinical, or EPI |
| WHO definition (reference) | X                  |                   |                        |                    |                                |       |       |      |                     |                |             |                     |                          |
| Argentina        | X                  | X                 |                          |                    |                                |       |       |      |                     |                |             |                     |                          |
| Bangladesh‡      | X                  | X                 |                          |                    |                                |       |       |      |                     |                |             |                     |                          |
| Brazil           | X                  | X                 |                          |                    |                                |       |       |      |                     |                |             |                     |                          |
| Chile            | X                  |                   |                          |                    |                                |       |       |      |                     |                |             |                     |                          |
| Colombia         | X                  |                   |                          |                    |                                |       |       |      |                     |                |             |                     |                          |
| France§          | X                  | X                 |                          |                    |                                |       |       |      |                     |                |             |                     |                          |
| Germany§         | X                  | X                 |                          |                    |                                |       |       |      |                     |                |             |                     |                          |
| India‡           |                    |                   |                          |                    |                                |       |       |      |                     |                |             |                     |                          |
| Indonesia        | X                  |                   |                          |                    |                                |       |       |      |                     |                |             |                     |                          |
| Iran             | X                  |                   |                          |                    |                                |       |       |      |                     |                |             |                     |                          |
| Iraq†            |                    |                   |                          |                    |                                |       |       |      |                     |                |             |                     |                          |
| Italy§           | X                  | X                 |                          |                    |                                |       |       |      |                     |                |             |                     |                          |
| Mexico           | X                  |                   |                          |                    |                                |       |       |      |                     |                |             |                     |                          |
| Pakistan‡        |                    |                   |                          |                    |                                |       |       |      |                     |                |             |                     |                          |
| Peru             | X                  |                   |                          |                    |                                |       |       |      |                     |                |             |                     |                          |
| Philippines‡     | X                  | X                 |                          |                    |                                |       |       |      |                     |                |             |                     |                          |
| Russia           | X                  | X                 |                          |                    |                                |       |       |      |                     |                |             |                     |                          |
| Saudi Arabia     | X                  |                   |                          |                    |                                |       |       |      |                     |                |             |                     |                          |
| South Africa     | X                  |                   |                          |                    |                                |       |       |      |                     |                |             |                     |                          |
| Spain            | X                  | X                 |                          |                    |                                |       |       |      |                     |                |             |                     |                          |
| Turkey           | X                  |                   |                          |                    |                                |       |       |      |                     |                |             |                     |                          |
| Ukraine          | X                  |                   |                          |                    |                                |       |       |      |                     |                |             |                     |                          |
| United Kingdom   | X                  |                   |                          |                    |                                |       |       |      |                     |                |             |                     |                          |
| USA              | X                  |                   |                          |                    |                                |       |       |      |                     |                |             |                     |                          |

% of countries¶ 72% 40% 8% 28% 4% 4% 28% 4% 4% 4% 24% 12% 16% 24% 8%

* X indicates the criterion was sufficient for, or a potential component of, the confirmed case definition requirement(s). Full confirmed case definitions can be found in Appendix Table 6.
†Refer to probable case definition for applicable country (Appendix Table 6).
‡World Health Organization definition (confirmed case definition did not change between March 2020 and August 2020 update).
§European Centre for Disease Prevention and Control definition.
¶Denominator is 25 countries with confirmed case definitions.
Appendix Table 8. COVID-19 testing policies for asymptomatic persons in 25 countries with highest case counts as of January 1, 2021*  

| Countries          | Asymptomatic testing | EPI Criteria: Confirmed contact | EPI Criteria: Healthcare employee |
|--------------------|----------------------|---------------------------------|----------------------------------|
| WHO                | Yes with EPI Criteria| Yes                             |                                  |
| Iraq               | Yes with EPI Criteria| Yes                             |                                  |
| Bangladesh         | No                   |                                  |                                  |
| Philippines        | Yes                  |                                  |                                  |
| India              | Yes with EPI Criteria| Yes                             | Yes                              |
| Pakistan           | No                   |                                  |                                  |
| United States      | Yes                  |                                  |                                  |
| Italy              | Yes                  |                                  |                                  |
| Germany            | Yes with EPI Criteria| Yes                             | Yes                              |
| France             | Yes                  |                                  |                                  |
| Brazil             | Yes with EPI Criteria| Yes                             | Yes                              |
| Russia             | Yes                  |                                  |                                  |
| Colombia           | No                   |                                  |                                  |
| Peru               | No                   |                                  |                                  |
| Argentina          | No                   |                                  |                                  |
| Spain              | Yes with EPI Criteria| Yes                             | Yes                              |
| Mexico             | No                   |                                  |                                  |
| South Africa       | Yes with EPI Criteria| Yes                             |                                  |
| United Kingdom     | No                   |                                  |                                  |
| Iran               | Yes with EPI Criteria| Yes                             |                                  |
| Chile              | Yes                  |                                  |                                  |
| Saudi Arabia       | No                   |                                  | Yes                              |
| Turkey             | Yes with EPI Criteria| Yes                             | Yes                              |
| Indonesia          | No                   |                                  |                                  |
| Israel             | Yes                  |                                  |                                  |
| Ukraine            | No                   |                                  |                                  |

*EPI, epidemiologic; WHO, World Health Organization.
References

1. World Health Organization. Public health surveillance for COVID-19: interim guidance, 7 August 2020 [cited 2020 Dec 13]. https://apps.who.int/iris/handle/10665/333752

2. Argentina Ministry of Health. Case definition [in Spanish]. 2020 [cited 2020 Jan 4].
   https://www.argentina.gob.ar/salud/coronavirus-COVID-19/definicion-de-caso

3. Argentina Ministry of Health. Consensus on the use of diagnostic tests for SARS-CoV-2 [in Spanish] [cited 2020 Dec 4]. https://bancos.salud.gob.ar/sites/default/files/2020-09/covid-19-consenso-sobre-uso-de-pruebas-diagnosticas-para-sars-cov-2.pdf

4. Government of the People’s Republic of Bangladesh. National guidelines on clinical management of COVID-19. 2020 [cited 2020 Dec 4]. https://covidlawlab.org/wp-content/uploads/2021/01/Bangladesh_2020.11.05_Guideline_National-Guidelines-on-Clinical-Management-of-COVID-19_EN.pdf

5. Ministry of Health. Brazil. Epidemiological surveillance guide public health emergency of national importance for coronavirus disease 2019 [in Portuguese]. 2020 Aug 5 [cited 2020 Dec 3].
   https://portalarquivos.saude.gov.br/images/af_gvs_coronavirus_6ago20_ajustes-finais-2.pdf

6. Narbona P. Update on the definition of a suspected, confirmed and probable case for epidemiological surveillance in the face of a COVID-19 pandemic [in Spanish]. 2020 Oct 1 [cited 2021 Jan 4].
   https://www.minsal.cl/wp-content/uploads/2020/10/201006-Definici%C3%B3n-de-caso-sospechoso.pdf

7. Government of Chile. Action plan for coronavirus [in Spanish]. 2020 [cited 2020 Nov 30].
   https://www.gob.cl/coronavirus

8. Ministry of Health and Social Protection, Government of Colombia. Optimization of testing, tracking and isolation program for the monitoring and follow-up of COVID-19 cases and contacts in Colombia [in Spanish]. 2020 Oct 19 [cited 2020 Nov 30].
   https://www.minsalud.gov.co/Normatividad_Nuevo/Decreto%201374%20de%20202020.pdf

9. Ministry of Health and Social Protection, Government of Colombia. Testing, tracking and sustainable selective insulation [in Spanish]. 2020 [cited 2020 Dec 4].
   https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RISE/VS/ED/VSP/abece-prass.pdf
10. European Centre for Disease Prevention and Control. Case definition for coronavirus disease 2019 (COVID-19), as of 29 May 2020 [cited 2020 Sep 16]. https://www.ecdc.europa.eu/en/covid-19/surveillance/case-definition

11. Ministry of Solidarities and Health, Government of France. RT-PCR, antigenic and salivary tests [in French]. 2020 [cited 2020 Dec 3]. https://solidarites-sante.gouv.fr/soins-et-maladies/maladies/maladies-infectieuses/coronavirus/tout-savoir-sur-la-covid-19/article/les-tests-rt-per-antigeniques-et-salivaires

12. Federal Ministry of Health. Germany. The national test strategy. 2020 [cited 2021 Jan 5]. https://www.zusammengegencorona.de/en/die-nationale-teststrategie/

13. Government of India. Clinical management protocol for COVID-19. 2020 [cited 2020 Oct 25]. https://www.mohfw.gov.in/pdf/UpdatedClinicalManagementProtocolforCOVID19dated03072020.pdf

14. Indian Council of Medical Research, Government of India. Advisory on strategy for COVID-19 testing in India. 2020 Sep 4 [cited 2020 Nov 25]. https://www.mohfw.gov.in/pdf/AdvisoryonstrategyforCOVID19TestinginIndia.pdf

15. Republic of Indonesia. Prevention and control guidelines coronavirus disease 2019 (COVID-19) [in Indonesian]. 2020 Jul 13 [cited 2020 Nov 27]. https://covid19.go.id/p/protokol/pedoman-pencegahan-dan-pengendalian-coronavirus-disease-covid-19-revisi-ke-5

16. Government of Indonesia. Q&A [in Indonesian]. 2020 [cited 2020 Dec 3]. https://covid19.go.id/tanya-jawab?page=2

17. Israel Ministry of Health. Testing for COVID-19. 2020 [cited 2020 Nov 30]. https://www.gov.il/en/Departments/General/corona-tests

18. Minister of Health, Government of Italy. Operational guidelines for carrying out rapid antigen tests by general practitioners and pediatricians of free choice [in Italian]. 2020 [ cited 2021 Jan 6]. https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2020&codLeg=76980&parte=1%20&serie=null

19. Secretary of Health, Government of Mexico. Standardized guidelines for the epidemiological and laboratory surveillance of viral respiratory disease [in Spanish]. 2020 [cited 2020 Jan 4]. https://coronavirus.gob.mx/wp-content/uploads/2020/09/Lineamiento_VE_y_Lab_Enf_Viral_Ago-2020.pdf
20. Government of Mexico. Update of the operational definition of suspicious case of viral respiratory disease [in Spanish]. 2020 Aug 24 [cited 2020 Sep 16].
https://www.gob.mx/cms/uploads/attachment/file/573732/Comunicado_Oficial_DOC_sospechosoERV_240820.pdf

21. Secretary of Health, Government of Mexico. Emerging statement on the use of tests for the detection of SARS-CoV-2 antigen in Mexico [in Spanish]. 2020 Nov 11 [cited 2020 Dec 3].
https://coronavirus.gob.mx/wp-content/uploads/2020/11/Prueba_antigenica_COVID_11Nov2020.pdf

22. National Institute of Health. Pakistan. Case definition for COVID-19. 2020 [cited 2020 Nov 27].
https://www.nih.org.pk/wp-content/uploads/2020/03/Case-Definition-for-COVID-19.pdf

23. Ministry of National Health Services. Pakistan. National testing guidelines: real-time polymerase chain reaction (RT-PCR) diagnostic test. 2020 [cited 2021 Dec 7].
https://storage.covid.gov.pk/new_guidelines/02July2020_20200701_National_Testing_Guidelines_for_(RT-PCR)_Diagnostic_Test_0103.pdf

24. Ministry of National Health Services. Pakistan. Testing Strategy Incorporating COVID-19 Antigen Detection Rapid Diagnostic Tests (Ag-RDT). 2020 [cited 2020 Jan 5].
https://storage.covid.gov.pk/new_guidelines/02December2020_20201202_TESTING_STRATEGY_INCORPORATING_COVID-19_ANTIGEN_DETECTION_RAPID_DIAGNOSTIC_TESTS_(Ag-RDT)_5302.pdf

25. Government of Peru. Epidemiological alert to the risk of intensification of community transmission of COVID-19 in the post-quarantine period, in Peru [in Spanish]. 2020 [cited 2020 Jan 4].
https://www.dge.gob.pe/portal/docs/alertas/2020/AE019.pdf

26. Government of Peru. Epidemiological alert for the application of diagnostic tests in cases of COVID-19 in Peru [in Spanish]. 2020 [cited 2020 Sep 30].
https://www.dge.gob.pe/portalnuevo/publicaciones/alertas-epidemiologicas/

27. Republic of the Philippines Department of Health. Further amendment to administrative order no. 2020–0013 dated 09 April 2020 entitled, “Revised administrative order no. 2020-0012, ‘guidelines for the implementation for the inclusion of the coronavirus disease 2019 (COVID-19) in the list of notifiable diseases for mandatory reporting to the Department of Health’ dated March 17, 2020.” 2020 [cited 2020 Jan 4]. https://doh.gov.ph/sites/default/files/health-update/ao2020-0013-B.pdf
28. Republic of the Philippines Department of Health. Amendment to department memorandum no. 2020–0258 entitled updated interim guidelines on expanded testing for COVID-19. 2020 Jul 6 [cited 2020 Dec 07]. https://www.doh.gov.ph/sites/default/files/health-update/dm2020-0258-A.pdf

29. Russian Federation. Temporary methodological recommendations prevention, diagnosis and treatment of new coronavirus infection (COVID-19) [in Russian]. 2020 [cited 2020 Dec 07]. https://xn--80aesfpebagmfb0a.xn--p1ai/doc/699/attach/mr_COVID-19_v9_.pdf

30. Russian Federation. Frequently asked questions. 2020 [cited 2020 Nov 30]. https://xn--80aesfpebagmfb0a.xn--p1ai/faq/?tags=39

31. Kingdom of Saudi Arabia. COVID-19 coronavirus disease guidelines. 2020 [cited 2020 Dec 14]. https://covid19.cdc.gov.sa/wp-content/uploads/2020/10/EN_COVID_19_Coronavirus_Disease_Guidelines_v2.0.pdf

32. Republic of South Africa. Coronavirus disease 2019 (COVID-19) caused by a novel coronavirus (SARS-CoV-2). 2020 [cited 2020 Nov 25]. https://www.nicd.ac.za/wp-content/uploads/2020/09/Guidelines-for-case-finding-diagnosis-and-public-health-response-in-South-Africa_18Aug2020.pdf

33. Republic of South Africa Department of Health. Statement by President Cyril Ramaphosa on progress in the national effort to contain the COVID-19 pandemic. 2020 Sep 16 [cited 2020 Dec 07]. https://sacoronavirus.co.za/2020/09/16/statement-by-president-cyril-ramaphosa-on-progress-in-the-national-effort-to-contain-the-covid-19-pandemic-3/

34. Government of Spain. Early detection, surveillance and control of COVID-19 [in Spanish]. 2020 [cited 2020 Jan 4]. https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/COVID19_Estrategia_vigilancia_y_control_e_indicadores.pdf

35. Republic of Turkey Ministry of Health. COVID-19 (SARS-CoV-2 infection) general information, epidemiology, and diagnosis [in Turkish]. 2020 [cited 2020 Dec 8]. https://covid19.saglik.gov.tr/Eklenti/39551/0/covid-19rehberigenelbilgilerepidemiyolojivetanipdf.pdf
36. Ministry of Health of Ukraine. Organization of medical care for patients with coronavirus disease (COVID-19) [in Ukrainian]. 2020 [cited 2021 Jan 04]. https://moz.gov.ua/article/ministry-mandates/nakaz-moz-ukraini-vid-28032020--722-organizacija-nadannja-medichnoi-dopomogi-hvorim-na-koronavirusnu-hvorobu-covid-19

37. Ministry of Health of Ukraine. COVID-19 pandemic in Ukraine [cited 2020 Dec 8]. https://covid19.gov.ua/en

38. UK Healthy Security Agency. COVID-19: investigation and initial clinical management of possible cases. 2020 [cited 2020 Nov 25]. https://www.gov.uk/government/publications/wuhan-novel-coronavirus-initial-investigation-of-possible-cases/investigation-and-initial-clinical-management-of-possible-cases-of-wuhan-novel-coronavirus-wn-cov-infection

39. UK National Health Service. Get tested for coronavirus (COVID-19) [cited 2020 Nov 30]. https://www.gov.uk/getting-tested-for-coronavirus

40. Centers for Disease Control and Prevention. Coronavirus Disease. 2019 (COVID-19) 2020 interim case definition, approved August 5, 2020. 2020 [cited 2020 Oct 13]. https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2020-08-05/

41. Centers for Disease Control and Prevention. Overview of testing for SARS-CoV-2 (COVID-19). 2020 [cited 2020 Dec 07]. https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html.